Adult Blood Lead Epidemiology and Surveillance Program (ABLES)



Headlines

Potential for Falsely Low Blood Lead Test Results from LeadCare® Analyzers- May 17, 2017 (PDF)
Summary - The U.S. Food and Drug Administration (FDA) has issued a safety communication warning about the use of Magellan Diagnostics’ LeadCare® analyzers (LeadCare, LeadCare II, LeadCare Ultra and LeadCare Plus) with venous blood samples because they might result in falsely low test results. FDA is now advising that Magellan Diagnostics’ LeadCare® analyzers should no longer be used with venous blood samples. The safety alert does not apply to capillary blood lead test results collected by fingerstick or heelstick. The purpose of this Health Advisory is to notify state and local health departments, healthcare providers, and laboratories about CDC’s re-testing guidance in light of the safety alert.

 


About Us

Learn more about the ABLES Program.



Reports

2009 Annual Report

2010 Annual Report

2011 Annual Report



Helpful Links

DSHS Laboratory Website

Texas Information & Referral Network

HUD Office of Lead Hazard Control

EPA Lead Program

US Consumer Product Safety Commission

US Occupational Safety and Health Administration (OSHA) Lead Standards



Related Websites

Texas Childhood Lead Poisoning Prevention Program

Blood Lead Surveillance Group

 


Comments? Questions?

Contact Us By Email

 

Mailing Address
PO Box 149347, MC 1964
Austin, Texas 78714-9347

Phone: 512-776-7151
Fax: 512-776-7699

 

Last updated May 18, 2017